Stacy Lindborg

6.2k total citations · 2 hit papers
25 papers, 4.2k citations indexed

About

Stacy Lindborg is a scholar working on Psychiatry and Mental health, Statistics and Probability and Clinical Psychology. According to data from OpenAlex, Stacy Lindborg has authored 25 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Psychiatry and Mental health, 9 papers in Statistics and Probability and 7 papers in Clinical Psychology. Recurrent topics in Stacy Lindborg's work include Schizophrenia research and treatment (12 papers), Statistical Methods in Clinical Trials (9 papers) and Bipolar Disorder and Treatment (5 papers). Stacy Lindborg is often cited by papers focused on Schizophrenia research and treatment (12 papers), Statistical Methods in Clinical Trials (9 papers) and Bipolar Disorder and Treatment (5 papers). Stacy Lindborg collaborates with scholars based in United States, Canada and United Kingdom. Stacy Lindborg's co-authors include Aaron L. Schacht, Daniel S. Mytelka, Christopher T. Dunwiddie, Bernard Munos, Steven M. Paul, Robert B. Zipursky, Alan Breier, Mauricio Tohen, Scott W. Woods and Diana O. Perkins and has published in prestigious journals such as American Journal of Psychiatry, Nature Reviews Drug Discovery and Biological Psychiatry.

In The Last Decade

Stacy Lindborg

25 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

How to improve R&D productivity: the pharmaceutical industry's grand challenge

2010 2.3k citations Steven M. Paul, Daniel S. Mytelka et al. Nature Reviews Drug Discovery profile →
Use of historical control data for assessing treatment effects in clinical trials

2013 327 citations Kert Viele, Scott Berry et al. Pharmaceutical Statistics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stacy Lindborg United States	18	1.1k	1.0k	830	544	466	25	4.2k
Robert Alexander United States	21	494 0.4×	692 0.7×	345 0.4×	103 0.2×	118 0.3×	68	3.0k
Robert C. Green United States	62	3.9k 3.4×	2.9k 2.7×	358 0.4×	992 1.8×	64 0.1×	342	16.7k
Steven Joffe United States	47	614 0.5×	858 0.8×	393 0.5×	1.3k 2.4×	55 0.1×	213	9.3k
Daniel Carpenter United States	27	1.7k 1.6×	165 0.2×	65 0.1×	573 1.1×	148 0.3×	60	3.5k
Roy Levy United States	33	991 0.9×	481 0.5×	48 0.1×	113 0.2×	116 0.2×	134	4.2k
Christopher Fowler Australia	37	1.6k 1.4×	1.4k 1.3×	145 0.2×	89 0.2×	23 0.0×	170	5.4k
Vural Özdemir Canada	29	599 0.5×	557 0.5×	87 0.1×	130 0.2×	24 0.1×	173	3.4k
Weichung Joe Shih United States	37	228 0.2×	1.2k 1.2×	86 0.1×	402 0.7×	10 0.0×	139	5.4k
Jonathan Kimmelman Canada	34	123 0.1×	1.2k 1.2×	85 0.1×	677 1.2×	23 0.0×	177	5.2k
Debu Tripathy United States	53	184 0.2×	4.2k 4.0×	143 0.2×	185 0.3×	17 0.0×	422	15.9k

Countries citing papers authored by Stacy Lindborg

Since Specialization

Citations

This map shows the geographic impact of Stacy Lindborg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stacy Lindborg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stacy Lindborg more than expected).

Fields of papers citing papers by Stacy Lindborg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stacy Lindborg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stacy Lindborg. The network helps show where Stacy Lindborg may publish in the future.

Co-authorship network of co-authors of Stacy Lindborg

This figure shows the co-authorship network connecting the top 25 collaborators of Stacy Lindborg. A scholar is included among the top collaborators of Stacy Lindborg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stacy Lindborg. Stacy Lindborg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cohen, Jeffrey A., Fred Lublin, Christopher Lock, et al.. (2022). Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis. Multiple Sclerosis Journal. 29(1). 92–106. 19 indexed citations

Kaspi, Haggai, et al.. (2021). MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model. Stem Cell Research & Therapy. 12(1). 72–72. 50 indexed citations

Riester, Katherine, Ludwig Kappos, Krzysztof Selmaj, et al.. (2019). Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis clinical trials. Multiple Sclerosis and Related Disorders. 39. 101865–101865. 5 indexed citations

Han, Baoguang, et al.. (2017). Covariate‐adjusted borrowing of historical control data in randomized clinical trials. Pharmaceutical Statistics. 16(4). 296–308. 34 indexed citations

Lindborg, Stacy, et al.. (2014). Statistical refocusing in the design of Phase II trials offers promise of increased R&D productivity. Nature Reviews Drug Discovery. 13(8). 638–640. 17 indexed citations

Viele, Kert, Scott Berry, Beat Neuenschwander, et al.. (2013). Use of historical control data for assessing treatment effects in clinical trials. Pharmaceutical Statistics. 13(1). 41–54. 327 indexed citations breakdown →

Paul, Steven M., Daniel S. Mytelka, Christopher T. Dunwiddie, et al.. (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery. 9(3). 203–214. 2338 indexed citations breakdown →

Lindborg, Stacy, et al.. (2008). Bayesian adaptive non-inferiority with safety assessment: Retrospective case study to highlight potential benefits and limitations of the approach. Journal of Psychiatric Research. 43(5). 561–567. 2 indexed citations

Barnes, Sunni A., et al.. (2007). The impact of missing data and how it is handled on the rate of false‐positive results in drug development. Pharmaceutical Statistics. 7(3). 215–225. 37 indexed citations

10.

McGlashan, Thomas H., Robert B. Zipursky, Diana O. Perkins, et al.. (2006). Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis. American Journal of Psychiatry. 163(5). 790–799. 403 indexed citations

11.

Barnes, Sunni A., Stacy Lindborg, & John W. Seaman. (2005). Multiple imputation techniques in small sample clinical trials. Statistics in Medicine. 25(2). 233–245. 82 indexed citations

12.

Kapur, Shitij, Tamara Arenovich, Ofer Agid, et al.. (2005). Evidence for Onset of Antipsychotic Effects Within the First 24 Hours of Treatment. American Journal of Psychiatry. 162(5). 939–946. 140 indexed citations

13.

Campbell, Gregory, et al.. (2005). Statistical issues: a roundtable discussion. Clinical Trials. 2(4). 364–372. 4 indexed citations

14.

Purdon, Scot E., Neil D. Woodward, Stacy Lindborg, & Émmanuel Stip. (2003). Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. Psychopharmacology. 169(3-4). 390–397. 62 indexed citations

15.

Miller, Tandy J., Robert B. Zipursky, Diana O. Perkins, et al.. (2003). The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. Schizophrenia Research. 61(1). 19–30. 120 indexed citations

16.

McGlashan, Thomas H., Robert B. Zipursky, Diana O. Perkins, et al.. (2003). The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. Schizophrenia Research. 61(1). 7–18. 166 indexed citations

17.

Woods, Scott W., Alan Breier, Robert B. Zipursky, et al.. (2003). Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry. 54(4). 453–464. 169 indexed citations

18.

Wright, Pádraig, Karena Meehan, Martin Birkett, et al.. (2003). A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clinical Therapeutics. 25(5). 1420–1428. 40 indexed citations

19.

Lindborg, Stacy, Charles M. Beasley, Karla Alaka, & Cindy C. Taylor. (2003). Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. Psychiatry Research. 119(1-2). 113–123. 35 indexed citations

20.

Battaglia, John, Stacy Lindborg, Karla Alaka, Karena Meehan, & Pádraig Wright. (2003). Calming versus sedative effects of intramuscular olanzapine in agitated patients. The American Journal of Emergency Medicine. 21(3). 192–198. 84 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact